Showing papers by "Walter W. Powell published in 2001"

To patent or not: Faculty decisions and institutional success at technology transfer

Abstract: We draw on qualitative data derived from field work on two university campuses to develop an explanation for widely disparate rates of new invention disclosure. We argue that faculty decisions to disclose are shaped by their perceptions of the benefits of patent protection. These incentives to disclose are magnified or minimized by the perceived costs of interacting with technology transfer offices and licensing professionals. Finally, faculty considerations of the costs and benefits of disclosure are colored by institutional environments that are supportive or oppositional to the simultaneous pursuit of academic and commercial endeavors.

A Comparison of U.S. and European University-Industry Relations in the Life Sciences

Abstract: We draw on diverse data sets to compare the institutional organization of upstream life science research across the United States and Europe. Understanding cross-national differences in the organization of innovative labor in the life sciences requires attention to the structure and evolution of biomedical networks involving public research organizations (universities, government laboratories, nonprofit research institutes, and research hospitals), science-based biotechnology firms, and multinational pharmaceutical corporations. We use network visualization methods and correspondence analyses to demonstrate that innovative research in biomedicine has its origins in regional clusters in the United States and in European nations. But the scientific and organizational composition of these regions varies in consequential ways. In the United States, public research organizations and small firms conduct R&D across multiple therapeutic areas and stages of the development process. Ties within and across these regions link small firms and diverse public institutions, contributing to the development of a robust national network. In contrast, the European story is one of regional specialization with a less diverse group of public research organizations working in a smaller number of therapeutic areas. European institutes develop local connections to small firms working on similar scientific problems, while cross-national linkages of European regional clusters typically involve large pharmaceutical corporations. We show that the roles of large and small firms differ in the United States and Europe, arguing that the greater heterogeneity of the U.S. system is based on much closer integration of basic science and clinical development.

Careers and contradictions: Faculty responses to the transformation of knowledge and its uses in the life sciences

Abstract: Drawing on interviews with more than 80 scientists on two university campuses, we create a typology that offers insights into how transformations in the nature and locus of life science innovation influence academic careers and work practices. Our analyses suggest that a strong outcome of increased academic concern with research commercialization is the appearance of new fault lines among faculty, between faculty and students, and even between scientists' interests and those of their institutions. We argue that life science commercialization is driven by a mix of new funding opportunities, changing institutional mandates for universities, and novel research technologies that bring basic research and product development into much closer contact. The rise of patenting and commercially motivated technology transfer on U.S. campuses stands to alter faculty work practices and relationships, while transforming the criteria by which success is determined and rewards are allocated. Through close analysis of interviews with four researchers who typify a range of academic responses to commercialism, we demonstrate emerging patterns of conflict and agreement in faculty responses to commercial opportunities in the life sciences.

Boundaries and New Organization Forms

Abstract: This article is a revision of the previous edition article by W.W. Powell, volume 2, pp. 1295–1298, © 2001, Elsevier Ltd.

Institutional Success at Technology Transfer

Abstract: We draw on qualitative data derived from field work on two university campuses to develop an explanation for widely disparate rates of new invention disclosure. We argue that faculty decisions to disclose are shaped by their perceptions of the benefits of patent protection. These incen- tives to disclose are magnified or minimized by the perceived costs of interacting with technology transfer offices and licens- ing professionals. Finally, faculty considerations of the costs and benefits of disclosure are colored by institutional environ- ments that are supportive or oppositional to the simultaneous pursuit of academic and commercial endeavors.

A Comparison of U.S. And European University-Industry Relations in the Life Sciences

Abstract: We draw on diverse data sets to compare the institutional organization of upstream life science research across the United States and Europe. Understanding cross-national differences in the organization of innovative labor in the life sciences requires attention to the structure and evolution of biomedical networks involving public research organizations (universities, government laboratories, nonprofit research institutes, and research hospitals), science-based biotechnology firms, and multinational pharmaceutical corporations. We use network visualization methods and correspondence analyses to demonstrate that innovative research in biomedicine has its origins in regional clusters in the United States and in European nations. But the scientific and organizational composition of these regions varies in consequential ways. In the United States, public research organizations and small firms conduct R&D across multiple therapeutic areas and stages of the development process. Ties within and across these regions link small firms and diverse public institutions, contributing to the development of a robust national network. In contrast, the European story is one of regional specialization with a less diverse group of public research organizations working in a smaller number of therapeutic areas. European institutes develop local connections to small firms working on similar scientific problems, while cross-national linkages of European regional clusters typically involve large pharmaceutical corporations. We show that the roles of large and small firms differ in the United States and Europe, arguing that the greater heterogeneity of the U.S. system is based on much closer integration of basic science and clinical development.